Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.

Al-Jamal, K.T., Al-Jamal, W.T., Akerman, S., Podesta, J.E., Yilmazer, A., Turton, J.A., Bianco, A., Vargesson, N., Kanthou, C., Florence, A.T., Tozer, G.M. and Kostarelos, K. (2010) Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proceedings of the National Academy of Sciences of the USA, 107 (9). pp. 3966-3971. 10.1073/pnas.0908401107 .

Full text not available from this repository.

DOI: 10.1073/pnas.0908401107

Abstract

This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G6) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead to solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay. Intravenous administration of the PLL-dendrimer molecules into C57BL/6 mice inhibited vascularisation in Matrigel plugs implanted subcutaneously. Antiangiogenic activity was further evidenced using intravital microscopy of tumors grown within dorsal skinfold window chambers. Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers. Also, the in vivo toxicological profile of the PLL-dendrimer molecules was shown to be safe at the dose regime studied. The antiangiogenic activity of the PLL dendrimer was further shown to be associated with significant suppression of B16F10 solid tumor volume and delayed tumor growth. Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment. This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems.

Item Type:Article
Uncontrolled Keywords:angiogenesis cancer nanoparticle
Departments, units and centres:Department of Pharmacology > Centre for Toxicology
ID Code:1549
Journal or Publication Title:Proceedings of the National Academy of Sciences of the USA
Deposited By:Library Staff
Deposited On:20 Apr 2010 16:24
Last Modified:04 May 2012 11:41

Repository Staff Only: Item control page

School of Pharmacy Staff Only: Edit a copy to replace this item